IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
60
About the Report
About the Report
Summary
IMV Inc (IMV), formerly Immunovaccine Inc, is a clinical-stage biopharmaceutical company that develops cancer immunotherapies and infectious disease vaccines. The company's product candidates include DPX-Survivac, a T cell activating immunotherapy that identifies and disrupts cancer biology in solid and hematological cancers; DPX-E7, an investigational immunotherapy that targets a viral protein in human papillomavirus in cervical and related cancers; and DPX-RSV, a lead infectious disease candidate is a small B cell epitope peptide vaccine intended to address the needs in respiratory syncytial virus. The company partners with various universities, research institutes and other vaccine development companies to develop its product candidates for applications in cancer and infectious diseases. IMV is headquartered in Halifax, Nova Scotia, Canada.
IMV Inc (IMV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
IMV Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IMV Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
IMV Enters into Partnership with Merck 11
PCI Biotech Enters into Agreement with IMV 12
Immunovaccine Enters into Agreement with Incyte 13
Immunovaccine Enters into Agreement with University of Edinburgh 14
Immunovaccine Extends Partnership with UConn Health 15
Immunovaccine Expands Agreement with Leidos 16
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 17
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 18
Equity Offering 19
IMV Plans to Raise up to USD150 Million in Public Offering of Securities 19
Immunovaccine Raises USD11.6 Million in Public Offering of Shares 20
Immunovaccine Raises USD7.4 Million in Public Offering of Shares 21
Immunovaccine Raises USD6 Million in Private Placement of Shares 22
Immunovaccine Raises USD6.2 Million in Private placement of Units 23
Immunovaccine Raises USD8.7 Million in Public Offering of Units 25
Immunovaccine Raise USD1.58 Million in Private Placement of Shares 27
Immunovaccine Withdraws Prospectus For Public Offering Of Shares For USD 6.8 Million 28
Immunovaccine Withdraws Private Placement Of Shares For USD 1 Million 29
Immunovaccine Completes Private Placement Of Shares For USD 4 Million 30
Immunovaccine Completes Private Placement Of Units For USD 1.6 Million 31
Immunovaccine Completes Private Placement Of Common Stock For USD 2.8 Million 33
IMV Inc-Key Competitors 34
IMV Inc-Key Employees 35
IMV Inc-Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Strategy And Business Planning 37
Sep 04, 2018: IMV Celebrates Grand Opening of New Facility in Dartmouth, Nova Scotia 37
Financial Announcements 38
Aug 08, 2018: IMV announces Q2 2018 financial results 38
May 14, 2018: IMV Announces Q1 2018 Financial Results 40
Mar 20, 2018: Immunovaccine Announces Year-End 2017 Financial Results 42
Nov 09, 2017: Immunovaccine Announces Third Quarter 2017 Financial Results 44
Aug 08, 2017: Immunovaccine Announces Financial Results for Quarter Ended June 30, 2017 45
May 10, 2017: Immunovaccine Announces Financial Results for Quarter Ended March 31, 2017 47
Mar 30, 2017: Immunovaccine Announces 2016 Year-End Results 48
Corporate Communications 51
Jun 07, 2018: IMV Appoints Julia P. Gregory to Board of Directors 51
May 31, 2018: Nasdaq Approves Listing of IMV Common Shares 52
Jan 18, 2018: Immunovaccine Appoints Joseph Sullivan as Senior Vice President of Business Development 53
Feb 03, 2017: Immunovaccine Appoints Seasoned Financial Executive Pierre Labbe as CFO 54
Product News 55
Jan 31, 2018: Published Study Demonstrates the Association Between Immunovaccine's Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression 55
Clinical Trials 56
Oct 05, 2017: Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Companys DepoVax-based Programs 56
Apr 12, 2017: Immunovaccine Announces Positive Year-Long Immunogenicity Data from Phase 1 Clinical Trial for Respiratory Syncytial Virus Vaccine Candidate 57
Other Significant Developments 58
May 10, 2018: IMV-Change of ticker on OTCQX from IMMVF to IMMVD 58
Aug 08, 2017: Immunovaccine Issues Second Quarter 2017 Letter to Shareholders 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
List of Figure
List of Figures
IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
IMV Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Deals By Therapy Area, 2012 to YTD 2018 9
IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IMV Enters into Partnership with Merck 11
PCI Biotech Enters into Agreement with IMV 12
Immunovaccine Enters into Agreement with Incyte 13
Immunovaccine Enters into Agreement with University of Edinburgh 14
Immunovaccine Extends Partnership with UConn Health 15
Immunovaccine Expands Agreement with Leidos 16
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 17
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 18
IMV Plans to Raise up to USD150 Million in Public Offering of Securities 19
Immunovaccine Raises USD11.6 Million in Public Offering of Shares 20
Immunovaccine Raises USD7.4 Million in Public Offering of Shares 21
Immunovaccine Raises USD6 Million in Private Placement of Shares 22
Immunovaccine Raises USD6.2 Million in Private placement of Units 23
Immunovaccine Raises USD8.7 Million in Public Offering of Units 25
Immunovaccine Raise USD1.58 Million in Private Placement of Shares 27
Immunovaccine Withdraws Prospectus For Public Offering Of Shares For USD 6.8 Million 28
Immunovaccine Withdraws Private Placement Of Shares For USD 1 Million 29
Immunovaccine Completes Private Placement Of Shares For USD 4 Million 30
Immunovaccine Completes Private Placement Of Units For USD 1.6 Million 31
Immunovaccine Completes Private Placement Of Common Stock For USD 2.8 Million 33
IMV Inc, Key Competitors 34
IMV Inc, Key Employees 35
IMV Inc, Other Locations 36
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.